

Appendix 6 (as submitted by the authors): Cost-effectiveness results for restricted treatment (F2 – F4)							
		<u>Compared to Common baseline (No Screening)</u>					
<u>Age range</u>	<u>Strategy</u>	<u>Cost</u>	<u>QALYs</u>	<u>ΔCost</u>	<u>ΔQALYs</u>	<u>ICER</u>	<u>Sequential ICER</u>
25-64	No screening	\$71,327	13.7649	-	-	-	-
	Screen & treat with PR	\$71,451	13.7676	\$124	0.0026	\$47,466	\$47,466*
	Screen & treat with G1:simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	\$71,556	13.7698	\$230	0.0048	\$47,573	\$47,573*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$71,557	13.7709	\$230	0.0060	\$38,298	\$38,298
45-64	No screening	\$83,334	12.1024	-	-	-	-
	Screen & treat with PR	\$83,473	12.1061	\$139	0.0036	\$38,333	\$38,333*
	Screen & treat with G1:simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	\$83,632	12.1090	\$298	0.0065	\$45,636	\$45,636*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$83,634	12.1107	\$300	0.0082	\$36,348	\$36,348
G1: genotype 1; G2/3: genotype 2 or 3; G4/5/6: genotype 4 or 5 or 6; PR = pegylated interferon plus ribavirin; QALY = quality-adjusted life-year; SIM = simeprevir; SOF/RBV = sofosbuvir plus ribavirin; IFN-Free DAA = interferon-free direct-acting antiviral agents; ICER = incremental cost-effectiveness ratio *Extendedly dominated = the combination of two other alternatives dominated the treatment.							